tbuckley/cabot-search huggingface dataset:
Formal education about medication errors in internal medicine clerkships.
Authors: Curtis J. Rosebraugh, Peter K. Honig, Sally Usdin Yasuda, John C. Pezzullo, David A. Flockhart, Raymond L. Woosley
Journal: JAMA (2001)

tion in recognition, identification, and prevention of such events in US undergraduate internal medicine clerkships has not been recently studied. We studied existing curricula about adverse drug reactions and interactions in US internal medicine clerkship programs. Methods. We conducted a survey of all US undergraduate internal medicine clerkship programs in the spring of 2000. A 2-page, 1-stage survey instrument was sent to all internal medicine clerkship directors (N=105) identified by using the Clerkship Directory in Internal Medicine (CDIM) membership directory. Repeat surveys were sent to nonresponders. We chose internal medicine clerkship programs because, based on national averages, medical students spend an average of 12 weeks in this rotation, the most of any required clinical experience. 3 Also, the discipline of internal medicine trains future physicians to care for patients with complex medical problems that frequently require multiple medications, which may place patients at an increased risk of experiencing an adverse drug reaction. 4 The survey questions addressed adverse event curricula and learning experiences. We specifically asked about total lecture hours, rotations with formal adverse drug event instruction, clerkship directors’ content knowledge of the Institute of Medicine report 1 on medical errors, and clerkship directors’ willingness to add adverse drug reaction/interaction educational modules. Descriptive statistics were computed for each survey question. Questions were asked with 1 to 5 Likert scale responses in which response 3 was used as the midline “undecided” anchor. Results. Of the program directors surveyed, 79 (75%) responded. The mean average of total formal lectures on all topics was 32 (range, 0-160) hours. Sixteen percent of internal medicine clerkships had formal lectures on adverse drug reactions/ interactions. Sixty-five percent of the programs surveyed responded that they would incorporate 1 or 2 (mean average, range 1-10) hours of educational material on adverse drug reactions/interactions, if educational modules were available. Interestingly, 35% of clerkship directors had little or no familiarity with the Institute of Medicine report on medical errors, even though this survey was performed during a period
Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment?
Authors: M. El-Alfy, C. Deloche, L. Azzi, B.A. Bernard, F. Bernerd, J. Coutet, V. Chaussade, C. Martel, J. Leclaire, F. Labrie
Journal: British Journal of Dermatology (2010)

Journal Article Skin responses to topical dehydroepiandrosterone: implications in antiageing treatment? Get access M. El‐Alfy, M. El‐Alfy Molecular Endocrinology, Oncology and Human Genomics Research Center, Laval University Hospital Research Center (CRCHUL) and Laval University, 2705 Laurier Boulevard, Quebec City, G1V 4G2 QC, Canada Search for other works by this author on: Oxford Academic Google Scholar C. Deloche, C. Deloche L'Oréal Recherche, Centre Charles Zviak, 92 583 Clichy, France Search for other works by this author on: Oxford Academic Google Scholar L. Azzi, L. Azzi Molecular Endocrinology, Oncology and Human Genomics Research Center, Laval University Hospital Research Center (CRCHUL) and Laval University, 2705 Laurier Boulevard, Quebec City, G1V 4G2 QC, Canada Search for other works by this author on: Oxford Academic Google Scholar B.A. Bernard, B.A. Bernard L'Oréal Recherche, Centre Charles Zviak, 92 583 Clichy, France Search for other works by this author on: Oxford Academic Google Scholar F. Bernerd, F. Bernerd L'Oréal Recherche, Centre Charles Zviak, 92 583 Clichy, France Search for other works by this author on: Oxford Academic Google Scholar J. Coutet, J. Coutet L'Oréal Recherche, Centre Charles Zviak, 92 583 Clichy, France Search for other works by this author on: Oxford Academic Google Scholar V. Chaussade, V. Chaussade L'Oréal Recherche, Centre Charles Zviak, 92 583 Clichy, France Search for other works by this author on: Oxford Academic Google Scholar C. Martel, C. Martel Molecular Endocrinology, Oncology and Human Genomics Research Center, Laval University Hospital Research Center (CRCHUL) and Laval University, 2705 Laurier Boulevard, Quebec City, G1V 4G2 QC, Canada Search for other works by this author on: Oxford Academic Google Scholar J. Leclaire, J. Leclaire L'Oréal Recherche, Centre Charles Zviak, 92 583 Clichy, France Search for other works by this author on: Oxford Academic Google Scholar F. Labrie F. Labrie Molecular Endocrinology, Oncology and Human Genomics Research Center, Laval University Hospital Research Center (CRCHUL) and Laval University, 2705 Laurier Boulevard, Quebec City, G1V 4G2 QC, Canada Correspondence: F. Labrie. E‐mail: fernand.labrie@endoceutics.com Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 5, 1 November 2010, Pages 968–976, https://doi.org/10.1111/j.1365-2133.2010.09972.x Published: 01 November 2010
CARDIAC ARRHYTHMIAS PRODUCED DURING RIGHT HEART CATHETERIZATION: REPORT OF TWO CASES OF TRANSIENT PARTIAL RIGHT BUNDLE BRANCH BLOCK
Authors: A RAVIN, S DRESSLER, G BRONFIN, A HURST
Journal: Annals of Internal Medicine (1950)

Excerpt Since Forssman1first passed a catheter into his own heart in 1929, the procedure of right heart catheterization has proved itself of great value in the study of the normal and pathologic ph...
Abstract P220: Exposure to Secondhand Smoke and the Risk of Stroke
Authors: Angela M Malek, Leslie A McClure, Mary Cushman, Daniel T Lackland
Journal: Circulation (2014)

Background: Stroke is a leading cause of death worldwide, and is a major public health concern in terms of morbidity, mortality, economic costs, and loss of productivity. While exposure to secondhand smoke (SHS) is a risk factor for cardiovascular disease, associations of SHS with risk of stroke have been inconsistent. Hypothesis: We investigated the hypotheses that SHS exposure is associated with increased incidence of stroke and stroke subtypes (ischemic stroke and hemorrhagic stroke) among non-smokers, including never and former smokers. Methods: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) study enrolled a U.S. population sample of 30,239 Caucasian and African-American men and women aged &gt;=45 years in 2003-7 and is following them for stroke outcomes. We calculated the hazard ratio (HR) of stroke among non-smokers with SHS exposure using Cox proportional hazard models. Results: The cohort, without prevalent smoking, stroke and TIA (n=21,743), included 62% Caucasians and 38% African-Americans, with 55% females. Twenty-three percent reported SHS exposure the year prior to enrollment, and these individuals were more likely to be younger, African-American, male (all p&lt;0.001), and have higher C-reactive protein (CRP) and white blood count (WBC) (p&lt;0.05) compared to those not exposed. SHS exposure was associated with a 31% increased risk of any stroke event after adjustment for demographic, socioeconomic, and behavioral factors (Table 1). The association was seen only in ischemic, but not hemorrhagic stroke. Associations were slightly diminished after adjusting for traditional stroke risk factors, and markedly attenuated to the null after further addition of inflammation markers. Conclusions: SHS exposure was not related to stroke after accounting for inflammation markers. Further research is needed to confirm these findings.
Patients' perspective of acute non-invasive ventilation (NIV) for decompensated type 2 respiratory failure (T2RF)
Authors: Muhammad Hasan, Muhammad Naveed, Hassan Burhan, Colin Smyth
Journal: European Respiratory Journal (2011)

Background:  A proportion of patients who receive NIV for decompensated T2RF subsequently become intolerant to it. Lack of patient understanding, inadequate medical supervision and/or explanation could potentially lead to poor patient compliance with NIV. We sought to explore patients9 experience and views on acute NIV.   Methods:  A satisfaction questionnaire was completed by patients within 24 hours of receiving acute NIV on a respiratory ward.   Results:  115 patients (65 male, median age 68) completed the study. 83% patients received NIV for 2 or more days. Patient responses are shown in table 1. NIV was stopped due to intolerance in 26 cases (mask discomfort 14, claustrophobia 9 and nausea 3). Intention to have NIV in future was not affected by ventilator pressures applied, duration of ventilation, or whether or not the patient had previously had NIV.   Conclusion:  A significant proportion of patients found NIV unpleasant and would refuse such treatment in future. Our data also highlights a lack of understanding of NIV by many patients receiving this therapy. Our findings have significant implications for patient education in respiratory units, as well as choice of equipment using NIV, both of which may impact on patient acceptance of therapy, and mortality.
Amlodipine induced-photosensitivity presenting as telangiectasia
Authors: S.A. Grabczynska, N. Cowley
Journal: British Journal of Dermatology (2000)

Journal Article Amlodipine induced‐photosensitivity presenting as telangiectasia Get access S.A. Grabczynska, S.A. Grabczynska Dermatology Department, Chelsea and Westminster Hospital, Fulham Road, London SW10 9NH, U.K.*Dermatology Department, East Surrey Hospital, Canada Avenue, Redhill, Surrey RH1 5RH, U.K. Search for other works by this author on: Oxford Academic Google Scholar N. Cowley N. Cowley Dermatology Department, Chelsea and Westminster Hospital, Fulham Road, London SW10 9NH, U.K.*Dermatology Department, East Surrey Hospital, Canada Avenue, Redhill, Surrey RH1 5RH, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 142, Issue 6, 1 June 2000, Pages 1255–1256, https://doi.org/10.1046/j.1365-2133.2000.03572.x Published: 01 June 2000
Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries
Authors: Dennis Falzon, Matteo Zignol, Ernesto Jaramillo, Fraser Wares, Susanne Carai, Tauhid Islam, Paul Nunn
Journal: European Respiratory Journal (2012)

Background: tuberculosis patients who are resistant to rifampicin, isoniazid, fluoroquinolones and second-line injectable drugs present a serious challenge to TB treatment programmes. In 2006, the World Health Organization (WHO) started surveillance for this condition, defined as extensive drug resistance (XDR-TB). We describe outcomes of XDR-TB patients started on treatment in 2008.  Methods: we used the latest data reported by countries to WHO by December 2011. Treatment regimens were known to differ between countries. Standardized definitions for outcomes were widely applied.  Results: 20 countries reported outcomes for a total of 641 XDR-TB cases. Most cases were reported by South Africa (345), Peru (70), Romania (53), Georgia (49), Brazil (45) and Namibia (20), with other countries reporting a median of two cases each (range 1-19). Overall treatment success was 23%, 34% of cases died, 22% failed treatment, 12% defaulted and 9% were not evaluated. Success of 50% or more was only achieved by countries managing 1-3 cases. In countries with >20 cases, deaths were highest in Namibia (90%) and South Africa (40%), and failures peaked in Brazil (80%) and Romania (55%). More than half the cases in Peru were either not evaluated or defaulted.  Conclusions: national data reported to WHO show less favourable outcomes for XDR-TB patients than have, to date, been published in the literature, and are similar to untreated tuberculosis. The high mortality in southern African countries may be associated with HIV co-morbidity and low access to anti-retroviral agents. Better optimization of regimens and support to potential defaulters is recommended.
Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial
Authors: P. Wolf, W. Weger, F.J. Legat, T. Posch-Fabian, A. Gruber-Wackernagel, M. Inzinger, W. Salmhofer, A. Hofer
Journal: British Journal of Dermatology (2011)

Treatment with the interleukin-12/23 antibody ustekinumab produces a satisfactory response [i.e. 75% reduction in Psoriasis Area and Severity Index (PASI) compared with baseline (PASI 75)] in the majority of patients with moderate to severe chronic plaque-type psoriasis.To determine whether concomitant 311-nm ultraviolet (UV) B therapy can further enhance the response in patients with psoriasis treated with ustekinumab.Ten patients (five women and five men; mean age 58years, range 48-66) with moderate to severe plaque-type psoriasis were treated with ustekinumab at a standard dosage of 45 or 90mg subcutaneously depending on body weight (below or above 100kg) at weeks 0 and 4. Within 2days after ustekinumab initiation, the minimal erythemal dose (MED) was determined and suberythemal MED 311-nm UVB-based phototherapy was thereafter administered to one randomly selected body half (left or right, excluding the head) three times weekly for 6weeks. Treatment response was monitored weekly in terms of half-body PASI.Nine patients completed the study. Analysis of their data showed that 311-nm UVB significantly accelerated the therapeutic response. At baseline (i.e. start of 311-nm UVB therapy), the mean PASI was similar in both irradiated and unirradiated body halves (13·6 vs. 13·3). At week 6, however, it was lower on irradiated body halves (2·5 vs. 6·1). This difference of 3·6 (95% confidence interval 1·3-5) was statistically significant and corresponded to an overall mean PASI reduction from baseline of 82% vs. 54%, respectively. At week 6, PASI 75 was achieved significantly more often on UV-irradiated body halves than on unirradiated body halves [7/9 patients (78%) vs. 1/9 (11%)] (McNemar test, P=0·007). At week 12, this synergistic effect of 311-nm UVB was still apparent although not significantly so.Treatment with 311-nm UVB accelerates the clearance of psoriatic lesions in ustekinumab-treated patients.
Methadone Maintenance Therapy and Chronic Pain—Reply
Authors: Jon Streltzer, Thomas R Kosten
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract MP07: Increased Risk of Death in Individuals with Premature Atrial, but not Premature Ventricular Contractions on Screening Electrocardiogram
Authors: Amit J Shah, Yabing Li, Elsayed Z Solman
Journal: Circulation (2014)

Introduction: Premature atrial contractions (PACs) and premature ventricular contractions (PVCs) detected by long-term electrocardiographic recording have been found to be a marker of increased cardiovascular risk. However, the prognostic significance of PACs and PVCs detected by routine 12-lead screening electrocardiogram (ECG) is not well-established. Methods: We investigated the association between PACs and PVCs detected by a single 12-lead ECG with the risks of death from any cause, cardiovascular (CVD) disease, and ischemic heart disease (IHD) in a nationally representative, community-dwelling cohort of 7642 individuals enrolled in the Third Health and Nutrition Examination Survey (NHANES III). Individuals with known coronary artery disease, congestive heart failure, paced rhythms, and atrial fibrillation were excluded. Results: Mean age was 60 (± 14) years, 53% were women, 24% were non-Hispanic black, and 23% were Hispanics. PACs were detected in 94 (1.2%) participants while PVCs were detected in 114 (1.5%). Over a follow up period of up to 18 years, the death rates per 1000 person-years were 97, 40, and 21 for all-cause, CVD, and IHD deaths, respectively. In a demographic adjusted model, presence of PACs was associated with 50%, 78% and 151% increased risk of all-cause death, CVD death, and IHD death, respectively. After further adjustment for CVD risk factors, ECG abnormalities, concomitant comorbidities and potential confounders, these risks remained significantly high (Table). For PVCs, however, no significant associations with any type of deaths in any model were detected. Conclusion: PACs, but not PVCs, on routine screening ECG are predictive of adverse events in community-dwelling individuals without known heart disease. Given the low cost and widespread use of 12-lead ECG, these findings warrant further investigation into mechanisms and interventions.
A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours.
Authors: PM Calvert, O'Neill, AS Azzabi, AN Hughes, ER Plummer, C Twelves, A Robinson, MA Machan, S Dimitrijevic, D Moss, J Rothermel, P Cohen, T Chen, A Man, AH Calvert
Journal: Clinical Cancer Research (2000)
896. Local Direct Injection of BMP2-Modified Fibroblasts Induces Ectopic Bone Formation in Immunocompetent Mice
Authors: Flavia Borellini, Sally S. Seaver, Ian F. DeVeau, Beth M. Hutchins
Journal: Molecular Therapy (2004)

The United States Pharmacopeia (USP) is a nongovernmental, standards-setting organization that advances public health by ensuring the quality and consistency of medicines founded in 1820. USP standards are developed by a unique process of involvement by the scientific and regulatory communities and are accepted worldwide. Within the USP, the development of standards for gene therapy products is being lead by the Gene Therapy,  Therapy and Tissue Engineering Expert Committee (GCT). This group is composed of scientists and clinicians from academic medical centers, the biopharmaceutical industry, and various government agencies, including Health Canada, U.S. National Institutes of Health, U.S. National Institute of Standards and Technology and U.S. Food and Drug Administration (FDA). Activities of GCT include the development of the USP general information chapter   Cell and Gene Therapy Products, which became official in April 2002. This general chapter summarizes the issues and best current practices in the manufacturing, testing and administration of cell and gene therapy products. GCT is currently developing a general information chapter on the qualification of ancillary materials (also referred to as ancillary products, ancillary reagents, processing agents) used in the manufacture of gene and cell therapy products. The proposed general chapter   Ancillary Materials for Cell, Gene and Tissue-Engineered Products, will be published in the USP publication Pharmacopeial Forum in March 2004 for public review and comment. GCT is also working with other USP Expert Committees to revise the general chapter   Design and Analysis of Biological Assays. This presentation will outline the content and scope of USP general information chapters relevant to cell and gene therapy, and explain how the scientific community can become involved in the development of standards for gene therapy products at USP.
Violent deaths among the young: recent trends in suicide, homicide, and accidents
Authors: P C Holinger
Journal: American Journal of Psychiatry (1979)

Violent deaths (suicide, homicide, and accidents) are the leading cause of death in people aged 1--39 in the United States. All three types of violent death may represent suicidal tendencies. Among early (10--14 years), middle (15--19), and late (20--24) adolescents, suicide and homicide rates increased with age and have doubled from 1961 to 1975. Accident rates increased with age but have changed little over the 15-year period. Suicide, homicide, and accidents increased dramatically between the 10--14-year-old age group and the 15--19-year-old age group; suicide and homicide rates were remarkably parallel over time; and suicide rates among young white people were higher and increased more than those among young nonwhite people.
Drug Safety Monitoring
Authors: Tracy Hampton
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
European states agree to fund six year public health programme
Authors: Rory Watson
Journal: BMJ (2001)

European Union governments have agreed to allocate 280m euros (£172.7m; $241.7m) to help fund a new six year public health programme for their 15 member states.

The new strategy will concentrate on three main strands, leaving the organisation and delivery of health services and medical care in the hands of national authorities.

The priorities of the programme are establishing a comprehensive data system on the major determinants of health, such as the consumption of alcohol and tobacco; ensuring that the union is able to handle international health …